KMT2A-REARRANGED
Clinical trials for KMT2A-REARRANGED explained in plain language.
Never miss a new study
Get alerted when new KMT2A-REARRANGED trials appear
Sign up with your email to follow new studies for KMT2A-REARRANGED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: dual attack trial begins
Disease control Not yet recruitingThis early-stage study aims to find a safe and effective dose of two drugs, revumenib and blinatumomab, given together for adults with a specific genetic type of acute lymphoblastic leukemia (ALL). It will enroll about 20 adults, including those newly diagnosed and those whose ca…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat blood cancer: experimental combo enters human testing
Disease control Not yet recruitingThis early-stage study aims to find a safe dose and check side effects of combining two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. It will enroll about 24 adolescents and adul…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC